» Articles » PMID: 34677420

Molecular Mechanisms of the SLC13A5 Gene Transcription

Overview
Journal Metabolites
Publisher MDPI
Date 2021 Oct 22
PMID 34677420
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Citrate is a crucial energy sensor that plays a central role in cellular metabolic homeostasis. The solute carrier family 13 member 5 (SLC13A5), a sodium-coupled citrate transporter highly expressed in the mammalian liver with relatively low levels in the testis and brain, imports citrate from extracellular spaces into the cells. The perturbation of SLC13A5 expression and/or activity is associated with non-alcoholic fatty liver disease, obesity, insulin resistance, cell proliferation, and early infantile epileptic encephalopathy. SLC13A5 has been proposed as a promising therapeutic target for the treatment of these metabolic disorders. In the liver, the inductive expression of SLC13A5 has been linked to several xenobiotic receptors such as the pregnane X receptor and the aryl hydrocarbon receptor as well as certain hormonal and nutritional stimuli. Nevertheless, in comparison to the heightened interest in understanding the biological function and clinical relevance of SLC13A5, studies focusing on the regulatory mechanisms of SLC13A5 expression are relatively limited. In this review, we discuss the current advances in our understanding of the molecular mechanisms by which the expression of SLC13A5 is regulated. We expect this review will provide greater insights into the regulation of the gene transcription and the signaling pathways involved therein.

Citing Articles

Novel Approaches to Studying SLC13A5 Disease.

Beltran A Metabolites. 2024; 14(2).

PMID: 38392976 PMC: 10890222. DOI: 10.3390/metabo14020084.


Metabolic Signature of Warburg Effect in Cancer: An Effective and Obligatory Interplay between Nutrient Transporters and Catabolic/Anabolic Pathways to Promote Tumor Growth.

Mathew M, Nguyen N, Bhutia Y, Sivaprakasam S, Ganapathy V Cancers (Basel). 2024; 16(3).

PMID: 38339256 PMC: 10854907. DOI: 10.3390/cancers16030504.


The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development.

Gill D, Zagkos L, Gill R, Benzing T, Jordan J, Birkenfeld A BMC Med. 2023; 21(1):504.

PMID: 38110950 PMC: 10729503. DOI: 10.1186/s12916-023-03227-5.


Mapping the Metabolic Niche of Citrate Metabolism and .

Chen F, Willenbockel H, Cordes T Metabolites. 2023; 13(3).

PMID: 36984771 PMC: 10054676. DOI: 10.3390/metabo13030331.


SLC13A5 Deficiency Disorder: From Genetics to Gene Therapy.

Goodspeed K, Liu J, Nye K, Prasad S, Sadhu C, Tavakkoli F Genes (Basel). 2022; 13(9).

PMID: 36140822 PMC: 9498415. DOI: 10.3390/genes13091655.


References
1.
Inoue K, Fei Y, Zhuang L, Gopal E, Miyauchi S, Ganapathy V . Functional features and genomic organization of mouse NaCT, a sodium-coupled transporter for tricarboxylic acid cycle intermediates. Biochem J. 2003; 378(Pt 3):949-57. PMC: 1224018. DOI: 10.1042/BJ20031261. View

2.
Williamson M, Gasiewicz T, Opanashuk L . Aryl hydrocarbon receptor expression and activity in cerebellar granule neuroblasts: implications for development and dioxin neurotoxicity. Toxicol Sci. 2004; 83(2):340-8. DOI: 10.1093/toxsci/kfi031. View

3.
Huang L, Wang C, Xu H, Peng G . Targeting citrate as a novel therapeutic strategy in cancer treatment. Biochim Biophys Acta Rev Cancer. 2019; 1873(1):188332. DOI: 10.1016/j.bbcan.2019.188332. View

4.
Li L, Welch M, Li Z, Mackowiak B, Heyward S, Swaan P . Mechanistic Insights of Phenobarbital-Mediated Activation of Human but Not Mouse Pregnane X Receptor. Mol Pharmacol. 2019; 96(3):345-354. PMC: 6701513. DOI: 10.1124/mol.119.116616. View

5.
Emi Y, Ikushiro S, Iyanagi T . Xenobiotic responsive element-mediated transcriptional activation in the UDP-glucuronosyltransferase family 1 gene complex. J Biol Chem. 1996; 271(7):3952-8. DOI: 10.1074/jbc.271.7.3952. View